Clearside Biomedical, Inc. (CLSD)
CLSD moved a median of 0.00% 30 minutes after news, and -0.92% by the close. How CLSD actually reacts to news — the realized, point-in-time move the market made, measured across 145 labeled events over the last three years with zero look-ahead.
CLSD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 141 |
| 30-min | 0.00% | 46% | 143 |
| 60-min | 0.00% | 46% | 143 |
| to close | -0.92% | 41% | 143 |
| Middle 50% of CLSD reactions | -1.83% to +1.72% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 145 |
Half of all Clearside Biomedical, Inc. news events land between -1.83% and +1.72% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CLSD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 19 | -4.54% | 21% | -18.06% |
| Coverage initiations | 17 | -1.90% | 24% | -2.59% |
| Rating reiterations | 53 | +0.27% | 57% | -0.97% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CLSD ranks against every other measured name →
That’s how CLSD usually reacts — get an email when it moves on news →Email me when CLSD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLSD's baseline. Nothing else.
Recent CLSD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 25 Clearside Biomedical, | SEC filing · Form 25 | SEC EDGAR | — | — | |
| Form 8-K Clearside Biomedical, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Clearside Biomedical, For: Nov 23 | SEC filing · Form 8-K | SEC EDGAR | -2.56% | -4.21% | |
| Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process | Press release | GlobeNewswire | +0.51% | +9.74% | |
| Form 10-Q Clearside Biomedical, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.07% | -7.99% | |
| Form 8-K Clearside Biomedical, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.76% | |
| Form 8-K Clearside Biomedical, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -1.33% | +3.43% | |
| Form 8-K Clearside Biomedical, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +3.35% | -1.15% | |
| Form 8-K Clearside Biomedical, For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | +6.12% | |
| Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress | Press release | GlobeNewswire | -1.33% | -3.35% | |
| Form 8-K Clearside Biomedical, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | -5.20% | |
| Form 10-Q Clearside Biomedical, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.25% | +2.54% | |
| Form DEF 14A Clearside Biomedical, For: Aug 29 | SEC filing · Form DEF | SEC EDGAR | +1.95% | +3.77% | |
| Form PRE 14A Clearside Biomedical, For: Aug 29 | SEC filing · Form PRE | SEC EDGAR | -4.15% | -7.27% | |
| Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada | Press release | GlobeNewswire | -4.92% | +11.64% | |
| Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline | Press release | GlobeNewswire | +0.00% | -27.49% | |
| Form 8-K Clearside Biomedical, For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -27.49% | |
| Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Clearside Biomedical, For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | -3.91% | |
| Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum | Press release | GlobeNewswire | +2.31% | -2.71% | |
| Form 10-Q Clearside Biomedical, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.01% | +2.20% | |
| Form S-8 Clearside Biomedical, | SEC filing · Form S-8 | SEC EDGAR | -0.01% | +2.20% | |
| Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -0.54% | |
| Form 8-K Clearside Biomedical, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.54% | |
| Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting | Press release | GlobeNewswire | -1.26% | -1.29% | |
| Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 | Press release | GlobeNewswire | +0.00% | +0.43% | |
| Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference | Press release | GlobeNewswire | -3.35% | -3.62% | |
| Form ARS Clearside Biomedical, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.14% | -5.88% | |
| Form DEF 14A Clearside Biomedical, For: May 30 | SEC filing · Form DEF | SEC EDGAR | -0.14% | -5.88% | |
| Form DEFA14A Clearside Biomedical, | SEC filing · Form DEFA14A | SEC EDGAR | -0.14% | -5.88% | |
| Form PRE 14A Clearside Biomedical, For: May 30 | SEC filing · Form PRE | SEC EDGAR | -1.44% | -4.15% | |
| Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +4.44% | +0.84% | |
| Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.06% | -3.06% | |
| Form 10-K Clearside Biomedical, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.06% | -3.06% | |
| Form 8-K Clearside Biomedical, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +3.06% | -3.06% | |
| Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting | Press release | GlobeNewswire | +0.00% | +0.98% | |
| Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 | Press release | GlobeNewswire | +0.00% | +2.12% | |
| Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD | Press release | GlobeNewswire | +3.01% | +10.92% | |
| Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema | Press release | GlobeNewswire | +1.91% | -1.91% | |
| Form 8-K Clearside Biomedical, For: Feb 07 | SEC filing · Form 8-K | SEC EDGAR | +4.95% | +5.94% | |
| Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting | Press release | GlobeNewswire | -1.98% | -1.80% | |
| Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference | Press release | GlobeNewswire | +2.10% | +5.20% | |
| Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program | Press release | GlobeNewswire | +1.62% | +0.01% | |
| Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore | Press release | GlobeNewswire | -2.10% | +0.51% | |
| Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye | Press release | GlobeNewswire | -0.75% | -7.00% | |
| Form 8-K Clearside Biomedical, For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -1.06% | -0.97% | |
| Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.48% | -6.09% | |
| Form 10-Q Clearside Biomedical, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.48% | -6.09% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLSD section they belong to.
Where else CLSD is measured.
CLSD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
| BeyondSpring, Inc. - Ordinary Shares (BYSI) | 146 | 0.00% | 49% |
| Oramed Pharmaceuticals Inc. (ORMP) | 145 | +0.69% | 69% |
| GlycoMimetics, Inc. (GLYC) | 144 | +0.53% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Clearside Biomedical, Inc.'s median reaction calculated?
Every labeled CLSD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 145 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of CLSD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLSD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.